上海复星医药（集团）股份有限公司 2024 年度股东会 2025 年第一次 A 股类别股东会 2025 年第一次 H 股类别股东会 会议资料 股票简称： 复星医药 股票代码：600196.SH 02196.HK 中国·上海 二零二五年六月二十四日 上海复星医药（集团）股份有限公司 2024年度股东会、2025年第一次A股类别股东会及2025年第一次H股类别股东会会议资料 目 录 | 一、会议须知 | 1 | | --- | --- | | 二、会议安排 | 3 | | 三、2024年度股东会会议议程 | 4 | | 议案一：本集团 2024 年年度报告 | 6 | | 议案二：2024 年度董事会工作报告 | 7 | | 议案三：2024 年度监事会工作报告 | 9 | | 议案四：2024 年度利润分配预案 | 11 | | 议案五：关于本公司 2025 年续聘会计师事务所及 2024 年会计师事务所报酬的议案 | 12 | | 议案六：关于 2024 年本公司董事考核结果和报酬的议案 | 13 | | 议案七：关于 2025 年本公司董事考核方案的议案 | 15 | | 议案八：关于本集团续展及新增委托贷 ...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 (a joint stock limited company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code股份代號：02196） NOTIFICATION LETTER 通知信函 Dear Non-Registered Shareholders, 20 May 2025 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") －Notice of publication of annual general meeting circular, notice of annual general meeting and notice of 2025 first H shareholders class meeting (col ...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 (a joint stock limited company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） （Stock Code股份代號：02196） NOTIFICATION LETTER 通知信函 20 May 2025 Dear Registered Shareholders. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "Company") – Notice of publication of annual general meeting circular, notice of annual general meeting, notice of 2025 first H shareholders class meeting and forms ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 上 海 復 星 醫 藥（集 團）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 2025年第一次H股類別股東會通告 茲通告上海復星醫藥（集團）股份有限公司（「本公司」）謹訂於2025年6月24日（星期二）緊隨本公司股東 周年大會及2025年第一次A股類別股東會（或其任何續會）結束後假座中國上海市虹許路358號上海天 禧嘉福璞緹客酒店舉行本公司2025年第一次H股類別股東會（「H股類別股東會」），以考慮及酌情通過 （無論有否修訂）下列決議案。除非另有說明，否則本通告所用詞彙與本公司日期為2025年5月20日之 通函（「通函」）所界定者具有相同涵義。 特別決議案 1 1. 考慮及酌情通過建議授予回購H股之一般性授權： (1) 在下文第1(2)項的規限下，授權董事會於有 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲 明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 上 海 復 星 醫 藥（集 團）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 股東周年大會通告 玆通告上海復星醫藥（集團）股份有限公司（「本公司」）股東周年大會（「股東周年大會」）謹訂於2025年6 月24日（星期二）下午一時三十分假座中國上海市虹許路358號上海天禧嘉福璞緹客酒店舉行，以考慮 及酌情通過（無論有否修訂）下列決議案。除非另有說明，否則本通告所用詞彙與本公司日期為2025 年5月20日之通函（「通函」）所界定者具有相同涵義。 普通決議案 1 (1) 本公司下屆股東周年大會結束時； (2) 本公司任何股東會通過決議撤銷或更改本議案所述授權之時。 18. 考慮及酌情通過建議授予回購H股之一般性授權： (1) 在下文第18(2)項的規限下，授權董事會於有 ...

此乃要件 請即處理 閣下對本通函任何方面或應採取之行動如有任何疑問，應諮詢股票經紀或其他持牌證券交易商、銀行經理、律師、專 業會計師或其他專業顧問。 閣下如已售出或轉讓名下所有上海復星醫藥（集團）股份有限公司之股份，應立即將本通函連同隨附之代表委任表格交予 買主或承讓人、或經手買賣或轉讓之銀行、股票經紀或其他代理人，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不對因本通函全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 上 海 復 星 醫 藥（集 團）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 2024年年度報告 2024年度董事會工作報告 2024年度監事會工作報告 2024年度利潤分配預案 續聘審計機構 考核結果 考核方案 委託貸款╱借款額度 授信申請總額 授權處置上市證券 授予註冊發行公司債券之一般性授權 修訂募集資金管理制度 修訂關 ...

Core Viewpoint - Morgan Stanley has lowered the target price for Fosun Pharma by 4%, from HKD 14.2 to HKD 13.7, while maintaining a "Market Perform" rating [1] Financial Performance - The company’s earnings per share forecasts for 2025-2027 have been reduced by 4-11% due to weak earnings in Q1 2025, primarily impacted by the volume-based procurement (VBP) of generic drugs and a slowdown in new drug growth [1] Capital Expenditure - Morgan Stanley has also revised down its capital expenditure forecasts, indicating no significant acquisitions or new business investments expected [1]

Group 1 - The core viewpoint of the article highlights the decline of the artemisinin concept sector, which fell by 0.82%, ranking among the top declines in the concept sector [1][2] - Within the artemisinin concept sector, major companies such as Rundu Co., Zhejiang Medicine, and Kunming Pharmaceutical experienced significant declines, while only two stocks, Delong Huineng and Baiyunshan, saw increases of 1.06% and 0.37% respectively [1][2] - The article provides a detailed overview of the capital flow, indicating a net outflow of 58 million yuan from the artemisinin concept sector, with Rundu Co. leading the outflow at 43.43 million yuan [2] Group 2 - The article lists the top-performing concept sectors, with the military equipment restructuring concept leading with a gain of 3.92%, while the artemisinin concept was among the worst performers [2] - A table is provided showing the capital flow for various companies within the artemisinin concept, detailing their respective price changes and turnover rates, with Rundu Co. showing a significant outflow [2]

Market Performance - The market rebounded last week, with the China Securities Xinhua National Brand Index rising by 0.94% to 1666.03 points [1] - The Shanghai Composite Index increased by 0.76%, the Shenzhen Component Index by 0.52%, the ChiNext Index by 1.38%, and the CSI 300 Index by 1.12% [1] Strong Stock Performances - Notable strong performers in the brand index included BGI Genomics, which rose by 17.27%, and Yiling Pharmaceutical, which increased by 9.81% [1] - Other significant gainers included Stone Technology and Marubi Biological, which rose by 7.18% and 6.79%, respectively [1] Year-to-Date Stock Gains - Since the beginning of 2025, Marubi Biological has surged by 60.82%, leading the gains, followed by Shanghai Jahwa with a 46.72% increase and BGI Genomics with a 34.45% rise [2] - Other stocks with notable increases include Anji Technology, Xintai, and Weir Shares, each rising over 20% [2] Market Outlook - Institutions expect the market to refocus on domestic economic fundamentals, with a positive policy response anticipated [2][3] - The current market is viewed as being in a high cost-performance range, with significant policy support expected to stabilize the economy and market [2] Economic Data Focus - Attention is drawn to upcoming economic data, particularly export performance and the sustainability of the export supply chain recovery [3] - The prevailing market conditions are supported by policy measures and liquidity easing, which are expected to bolster the stability of the domestic economy and capital markets [3]

Core Viewpoint - SaiLu Medical has completed A+ round financing led by Fosun Pharma, with funds aimed at upgrading domestic sequencing platforms and expanding market presence, driving innovation in life science tools [1][2]. Group 1: Financing and Investment - The A+ round financing was led by Fosun Pharma, with participation from Weichi Investment and existing shareholder Shenzhen Capital Group [2]. - The funds will be primarily used for the registration and declaration of domestic sequencing platforms, capacity expansion, and global market development [2][3]. Group 2: Company Development and Achievements - Since its establishment in 2020, SaiLu Medical has maintained rapid development, achieving significant milestones such as obtaining the NMPA Class III medical device registration for its Salus Pro sequencer in January 2025 [2]. - The company has built a comprehensive R&D system covering optics, fluidics, chips, and reagents, and has accumulated over 100 authorized patents [3]. Group 3: Strategic Collaboration - The financing marks a new phase of strategic cooperation between Fosun Pharma and SaiLu Medical, focusing on product development, resource integration, and global market expansion [6]. - Both companies will emphasize "innovation-driven" strategies to accelerate the development of innovative technologies and products that meet clinical needs [6].